CN112236453A - 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎 - Google Patents

使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎 Download PDF

Info

Publication number
CN112236453A
CN112236453A CN201980038401.7A CN201980038401A CN112236453A CN 112236453 A CN112236453 A CN 112236453A CN 201980038401 A CN201980038401 A CN 201980038401A CN 112236453 A CN112236453 A CN 112236453A
Authority
CN
China
Prior art keywords
chi
inhibitor
use according
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038401.7A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·布兰科
埃斯蒂巴利兹·拉扎罗
范妮·索韦斯特
奥雷利安·马特图伊齐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Original Assignee
Centre National de la Recherche Scientifique CNRS
Centre Hospitalier Universitaire de Bordeaux
Universite de Bordeaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Centre Hospitalier Universitaire de Bordeaux, Universite de Bordeaux filed Critical Centre National de la Recherche Scientifique CNRS
Publication of CN112236453A publication Critical patent/CN112236453A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/545—IL-1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
CN201980038401.7A 2018-06-14 2019-06-13 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎 Pending CN112236453A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305729 2018-06-14
EP18305729.8 2018-06-14
PCT/EP2019/065617 WO2019238893A1 (en) 2018-06-14 2019-06-13 Treatment of placental chronic histiocytic intervillositis using an inhibitor of interleukin-1

Publications (1)

Publication Number Publication Date
CN112236453A true CN112236453A (zh) 2021-01-15

Family

ID=62791692

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038401.7A Pending CN112236453A (zh) 2018-06-14 2019-06-13 使用白细胞介素-1抑制剂治疗胎盘慢性组织细胞绒毛间质炎

Country Status (5)

Country Link
US (1) US20210115131A1 (enExample)
EP (1) EP3807313A1 (enExample)
JP (1) JP2021527107A (enExample)
CN (1) CN112236453A (enExample)
WO (1) WO2019238893A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301263A (en) 2020-11-18 2023-05-01 Novartis Ag BISPECIFIC ANTIBODIES FOR USE IN THE TREATMENT OF NLRC4-GOF INFLAMMASOMAPATHY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
US20110184254A1 (en) * 2009-11-25 2011-07-28 Grove Thomas H Detection of intraamniotic infection

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1404400A (zh) * 2000-02-21 2003-03-19 应用研究系统Ars股份公司 Il－18抑制剂的应用
CN1565620A (zh) * 2003-06-09 2005-01-19 上海复旦张江生物医药股份有限公司 白细胞介素－1受体拮抗剂治疗非典型性肺炎的用途
US20110184254A1 (en) * 2009-11-25 2011-07-28 Grove Thomas H Detection of intraamniotic infection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ATIS MUEHLENBACHS等: "Genome-Wide Expression Analysis of Placental Malaria Reveals Features of Lymphoid Neogenesis during Chronic Infection", 《THE JOURNAL OF IMMUNOLOGY》 *
NOBUAKIOZAWA等: "Chronic histiocytic intervillositis in three consecutive pregnancies in a single patient: Differing clinical results and pathology according to treatment used", 《J. OBSTET. GYNAECOL. RES.》 *
孙燕等: "复发性流产患者绒毛组织中白细胞介素-6和白细胞介素-18的表达", 《广东医学》 *

Also Published As

Publication number Publication date
WO2019238893A1 (en) 2019-12-19
JP2021527107A (ja) 2021-10-11
EP3807313A1 (en) 2021-04-21
US20210115131A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
Crimi et al. Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: a real-world retrospective pilot study
Palmer et al. Bentamapimod (JNK inhibitor AS602801) induces regression of endometriotic lesions in animal models
Toldo et al. Interleukin‐1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse
Loretelli et al. The IL-8-CXCR1/2 axis contributes to diabetic kidney disease
Morita et al. Biologics for allergic and immunologic diseases
Lamacchia et al. The severity of experimental arthritis is independent of IL-36 receptor signaling
JP2019065029A (ja) 処置方法
JP2014193920A (ja) 子癇前症または子癇の診断方法および治療方法
Hvidtfeldt et al. Airway hyperresponsiveness reflects corticosteroid-sensitive mast cell involvement across asthma phenotypes
AU2006272913A1 (en) Methods of detecting and treating acute kidney injury
JP6502863B2 (ja) 結腸直腸癌を処置する方法
TW201946657A (zh) 治療潰瘍性結腸炎之方法
Nishiyama et al. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease
JP2024163308A (ja) Ｉｌ３３及びｉｌ１ｒｌ１をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
CA2962944A1 (en) Use of reslizumab to treat moderate to severe eosinophilic asthma
KR101426689B1 (ko) Ｎｕｔｌｉｎ­３ａ 화합물을 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
EP4371573A1 (en) Medicinal composition for treating inflammatory bowel disease
Zheng et al. Placental expression of AChE, α7nAChR and NF-κB in patients with preeclampsia
Hsu et al. Effect of selective cysteinyl leukotriene receptor antagonists on airway inflammation and matrix metalloproteinase expression in a mouse asthma model
Harvitkar et al. The laser therapy for hemorrhoidal disease: A prospective study
Han et al. The intervention effect of nicotine on cervical fibroblast-myofibroblast differentiation in lipopolysaccharide-induced preterm birth model through activating the TGF-β1/Smad3 pathway
US20210115131A1 (en) Treatment of Placental Chronic Histiocytic Intervillositis Using an Inhibitor of Interleukin-1
Matsumoto et al. Minimal-change nephrotic syndrome associated with subcutaneous eosinophilic lymphoid granuloma (Kimura’s disease)
TW201514497A (zh) Ｓｇｌｔ２作爲慢性腎臟疾病之診斷及追蹤治療後病況之生物標記
Bohm et al. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210115

WD01 Invention patent application deemed withdrawn after publication